Therapeutics News

Cyclopentolate 1% and tropicamide 1% had similar efficacies for cycloplegic refraction in youth and adults without strabismus, according to a study.

Twice-daily cyclosporine ophthalmic emulsion 0.09% significantly improved signs of dry eye disease in patients who were inadequately controlled with cyclosporine ophthalmic emulsion 0.05%, according to a study presented at SECO 2025.

Orasis Pharmaceuticals is announcing the U.S. launch of Qlosi at SECO 2025 in Atlanta.

Extended preoperative use of topical glaucoma medications with preservatives may negatively affect long-term trabeculectomy outcomes, according to a study published in Scientific Reports.

NEW YORK — In this presentation from OSN New York, Pete Setabutr, MD, of University of Illinois, Chicago, highlights nontraditional techniques to manage eyelid malposition.

Every year Healio covers a wide range of optometry-related news from the FDA, and 2024 was no exception.

INDIANAPOLIS — A single spray of MydCombi administered via the Optejet dispenser was comparable in efficacy to the label recommendation of two sprays in inducing clinically relevant mydriasis, according to researchers at Academy 2024.

An escalating monotherapy regimen was just as effective as multitherapy for most patients with untreated glaucoma, although those with higher baseline IOP may benefit from more intensive treatment, according to a study conducted in Sweden.

INDIANAPOLIS — Individuals with mild to moderate presbyopia who were treated with CSF-1 were able to achieve and maintain functional vision for at least 5 hours after two doses, according to a presenter at Academy 2024.